Sanolla

Sanolla is providing new diagnosis, monitoring and screening technology for cardiopulmonary diseases. The technology is based on full spectrum auscultation, including picking up low-frequency infra-sound (below 30 Hz). Artificial intelligence applications provide disease classification. Sanolla is bring two products to market: the VoqX smart stethoscope for physicians, nurses and paramedics, and the PyXy home monitoring early exacerbation detection device for CHF, COPD and asthama patients. The VoqX stethoscope is FDA cleared and will be brining disease classifciation for AS, AR, MR, COPD, CHF, asthma and pneumonia. The PyXy is being developed under the European Commission Horizon 2020 grant and is expected to be ready for commercial sales in 2023.